Life Technologies Establishes International Influenza Network

        Life Technologies Establishes International Influenza Network

-- Scientists at leading public health agencies and research institutes
collaborate to develop faster, more reliable flu subtyping methods

-- Partners sharing data on Life's Ion Torrent next-generation semiconductor
sequencing platform for global cooperative influenza monitoring and vaccine

PR Newswire

CARLSBAD, Calif., Jan. 29, 2013

CARLSBAD, Calif., Jan. 29, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) today announced the establishment of the Global Influenza
Network, a partnership including scientists at a number of the world's leading
government public health organizations, veterinary agencies and research
institutes in a collaborative effort to increase the speed and efficiency of
influenza monitoring and vaccine development. Members of the network are
sharing tools, experience and data using the Ion Personal Genome Machine
(PGM™) semiconductor sequencing platform.

"Life Technologies exhibited leadership in infectious disease trackingwhen
our scientists worked alongside federal officials to identify the cause of
H1N1 outbreak in 2008," said Gregory T. Lucier, Chairman and Chief Executive
Officer of Life Technologies. "We are very proud to now bring together a group
of such distinguished organizations to tackle the continued threat of
influenza worldwide."

Participating scientists include: Steve Glavas, head of the NGS Platform, and
Mia Brytting, Ph.D., head of the microbial typing unit at the Swedish
Institute for Communicable Disease Control (SMI); Gabriele Vaccari, Ph.D.,
researcher at the Istituto Superiore di Sanita in Rome; Mary Lea Killian,
microbiologist at the U.S. National Veterinary Service Laboratories in Ames,
Iowa; and David Wentworth at the J. Craig Venter Institute in Rockville, Md.

Partnership Develops Faster, More Reliable Flu Subtyping Methods

Annual seasonal influenza epidemics cause approximately 3 to 5 million cases
of severe illness and 250,000 to 500,000 deaths, according to the World Health
Organization (WHO). Pandemics caused by novel influenza strains can result in
staggering death tolls; the "Spanish flu" of 1918 is believed to have killed
40 million people, or 3 percent of the global population, according to the

Each year, public health agencies around the world collect samples from
infected individuals and share data about flu subtypes circulating in their
regions. The pooled data are used by the WHO to determine the strains used to
design a vaccine that will be effective against that year's epidemic. Costs of
sequencing, however, have limited data set to about 20 percent of the patient
samples collected.

"Using next generation sequencing technology makes whole influenza genome
sequencing much easier, and much less expensive than older sequencing
techniques, when used appropriately," said Glavas.

Scientists in the Global Influenza Network also believe that by sequencing all
patient samples collected ahead of the flu season, they will be able to detect
emerging strains earlier and focus resources on areas of the world where these
strains are most prevalent in order to better contain new threats.

An additional benefit of semiconductor sequencing is the technologies'
superior speed over conventional methods. Therefore, sequencing data can be
collected in a smaller time window prior to vaccine production, which can also
guide the production of vaccines so they more effectively target the strains
most prevalent in the coming flu season.

"Now we can easily fully characterize influenza causing severe outbreaks,"
said Brytting.

Network Scientists Confirm Protocol's Accuracy and Economic

The current collaboration is a pilot program to evaluate the efficacy of
influenza virus typing by semiconductor sequencing on Life Technologies' Ion
Torrent platform, the Ion PGM™ sequencer. After implementing Life
Technologies' protocol for whole genome sequencing of Influenza A virus, the
network partners determined it to be: (1) accurate; (2) highly sensitive and
(3) economical (less than $100 per isolate) because it enables scientists to
multiplex at least 10 samples in a single run on the Ion PGM™ sequencer.

Global Influenza Network partners have agreed to share their data and
experiences in order to refine the initial protocol, if needed. The results of
the collaborative study will be submitted to a peer-reviewed research journal
for publication.

The Ion Personal Genome Machine (PGM™) is Research Use Only and not intended
for use in diagnostic procedures.

About Life Technologies

Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
with customers in more than 160 countries using its innovative solutions to
solve some of today's most difficult scientific challenges. Quality and
innovation are accessible to every lab with its reliable and easy-to-use
solutions spanning the biological spectrum, with more than 50,000 products for
agricultural biotechnology, translational research, molecular medicine and
diagnostics, stem cell-based therapies, forensics, food safety and animal
health. Its systems, reagents and consumables represent some of the most cited
brands in scientific research including: Ion Torrent™, Applied
Biosystems®,Invitrogen™, Gibco®, Ambion®, Molecular Probes® and Novex®.Life
Technologiesemploys approximately 10,400 people and upholds its ongoing
commitment to innovation with more than 4,000 patents and exclusive licenses.
LIFE had sales of$3.7 billionin 2011. Visit us at our

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by Life Technologies with the Securities and Exchange
Commission. Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.


Life Technologies Contact
Suzanne Clancy
858-205-4235 (mobile)

SOURCE Life Technologies Corporation

Press spacebar to pause and continue. Press esc to stop.